Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
US11434259B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2017 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Jan 25, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika, dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.